Table 1.
Baseline characteristics of the cohorta
| Characteristic | Guideline-recommended dosing (n = 46) |
Non-guideline recommended dosing (n = 91) |
p-value |
|---|---|---|---|
| Male gender (%) | 80 | 81 | 0.90 |
| Age (years) | 56.5 (46, 73) | 57 (48, 67) | 0.93 |
| Race (%) | 0.30 | ||
| Caucasian | 63 | 76 | |
| African American | 13 | 7 | |
| Other | 2 | 4 | |
| Height (cm) | 173 (165, 178) | 175 (170, 183) | 0.008 |
| Weight (kg) | 65 (56, 75) | 89 (77, 102) | <0.001 |
| Serum creatinine (mg/dl) | 1.0 (0.7, 1.4) | 1.0 (0.7, 1.4) | 0.91 |
| Pitt Bacteremia Score | 3 (2, 4) | 3 (1, 6) | 0.38 |
| Concomittantnephrotoxins (%) | 67 | 58 | 0.30 |
| Infection source (%) | 0.11 | ||
| Bloodstream catheter related | 30 | 24 | |
| Pulmonary | 24 | 29 | |
| Skin/muscle | 11 | 27 | |
| Genitourinary | 7 | 4 | |
| Osteomyelitis | 0 | 2 | |
| Central nervous system | 0 | 1 | |
| Gastrointestinal | 0 | 1 | |
| Abcess | 0 | 1 | |
| Other | 28 | 11 | |
| Length of hospital stay (days) | 22 (11, 61) | 28 (16, 45) | 0.96 |
| ICU length of stay (days) | 11 (4, 22) | 9 (4, 27) | 0.78 |
| Initial vancomycin dose (mg/kg/day) | 31.2 (26.7, 35.9) | 20.6 (15.7, 24.4) | <0.001 |
| Vancomycin 1 gram every 12 hours | 33% | 44% | 0.20 |
| Initial vancomycin trough (mg/dl) | 13.9 (9.1, 18.8) | 10.6 (7.6, 16.4) | 0.10 |
| Initial vancomycin trough > 15 mg/dl (%) |
50 | 32 | 0.04 |
| Vancomycin duration (days) | 15 (8, 21) | 13 (8, 19) | 0.65 |
a
= Results are presented as median (interquartile range) unless otherwise noted.